RxDoctor Payments Data

Kun Chen, MD

Rheumatology · Huntsville, ALNPI 1730380056

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.2% of the total across 1,148 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by AbbVie at 29.5% of the total.

$21,696in general payments, 2019–2025

Across 1,148 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Amgen$3K
  • UCB, Inc.$2K
  • Novartis$1K
  • GSK$1K
  • Johnson & Johnson$1K
  • plus $6K from 32 others

What the payments were for

  • Consulting fees$5102%
  • Food & beverage$20,88196%
  • Education$3061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,696 in reported general payments places this provider in the 80th percentile of 90 rheumatology providers in Alabama.

See all rheumatology providers in Alabama

Medicare billing

Part B allowed, 2024
$2,922,312
Medicare patients
798
Services billed
197,354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab176$1,388,008
Enbrel SureclickEtanercept69$549,909
RinvoqUpadacitinib71$538,708
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5012$227,394
Humira(Cf)Adalimumab29$219,279
Cosentyx Unoready PenSecukinumab16$154,395
OrenciaAbatacept24$139,102
Xeljanz XrTofacitinib Citrate23$133,327
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$95,106
TymlosAbaloparatide19$50,089
Actemra ActpenTocilizumab15$43,080
Hydroxychloroquine Sulfate740$39,404
Teriparatide11$30,043
MethotrexateMethotrexate Sodium1,088$29,219
Leflunomide134$7,680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$6,392$757,987100 claims
E.r. Squibb & Sons, L.L.C.Orencia$650$139,10224 claims
Radius Health, Inc.Tymlos$276$50,08919 claims
Scilex Pharmaceuticals Inc.Colchicine$17$4,54254 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 90 rheumatology providers in Alabama.

Other rheumatology in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →